Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01592097|
Recruitment Status : Completed
First Posted : May 7, 2012
Last Update Posted : May 3, 2018
Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its clinical effect in the Hispanics with MS given that clinical studies had limited representation of this population. It is also unclear if Gilenya would be as effective in individuals with disease predominantly affecting the optic nerve and spinal cord (OSMS) commonly seen in Asian populations.
Objectives: To compare the clinical response of Gilenya® (fingolimod) in relapsing remitting OSMS and MS of Hispanic descent using ancestral markers as a biomarker of treatment response and clinical disease state.
|Condition or disease|
The primary objective of this study is to determine the success of Gilenya® (fingolimod) treatment in patients with MS of Hispanic descent relative to their ancestral background. Therapeutic success will be determined by annualized relapse rate (ARR; defined as the number of relapses divided by the person years followed) after initiation of treatment with Gilenya® (fingolimod)in comparison to the relapse rate in the previous 12 months. This will be determined based on medical chart extraction, in-person assessment and regular clinical follow-up.
A secondary objective of this study is to investigate whether the efficacy of Gilenya® (fingolimod) is superior or equal in HW which have higher loads of Amerindian versus Caucasian background with opticospinal MS (OSMS-NMO neg) versus classical MS (CMS) in the first 12 months using radiological and clinical parameters. The following measures will be obtained:
- Number of relapse-free patients over the investigational period
- Site of relapse defined as brain or spinal cord.
- Sustained Disability progression will be defined as a one point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5-5.5 or above after 3 months.
- MRI changes as described as number of new T2 lesions and number of Gd-enhancing lesions after 12 months from baseline.
|Study Type :||Observational|
|Actual Enrollment :||51 participants|
|Official Title:||A Non-randomized, Exploratory, Study to Assess Clinical Response to Gilenya® (Fingolimod) in a Cohort of Relapsing Remitting Hispanic MS Forms|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||April 2018|
|Actual Study Completion Date :||April 2018|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01592097
|United States, California|
|Keck School of Medicine of the University of Southern Calfornia|
|Los Angeles, California, United States, 90033|
|Principal Investigator:||Lilyana Amezcua, MD||University of Southern California|